Includes pharmaceutical, herbal and street drugs by four classes and combinations, with molecular structure, links to additional information, and, for brand name drugs, indications and approval dates.
FDA Drug Approval News
- 1.13.2023 Rykindo for Schizophrenia, Bipolar I
- 1.6.2023 Leqembi for Alzheimer's Disease
- 12.16.2022 Vraylar as adjunct for MDD
- 11.17.2022 Sezaby for neonatal seizures
- 8.18.2022 Auvelity for MDD
- 6.29.2022 Venbysi XR for MDD and GAD